Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited. CUDC-907 is an oral, first-in-class, small molecule that is designed to inhibit both histone deacetylase (HDAC) and PI3K enzymes, which are members of common oncogenic pathways in haematological malignancies. We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): May 2016

Volume: 17

Issue: 5

Affiliations

[1 ] Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: younesa@mskcc.org.

[2 ] Sarah Cannon Research Institute, Nashville, TN, USA.

[3 ] Sarah Cannon Research Institute, Nashville, TN, USA; Florida Cancer Specialists, Sarasota, FL, USA.

[4 ] Memorial Sloan Kettering Cancer Center, New York, NY, USA.

[5 ] Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

[6 ] Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California, Los Angeles, CA, USA.

[7 ] Curis, Inc, Lexington, MA, USA.

Article

Publisher Item ID: S1470-2045(15)00584-7 Mid ID: NIHMS866417

DOI: 10.1016/S1470-2045(15)00584-7

PMC ID: 5494693

PubMed ID: 27049457

SO-VID: addc9ddd-9b8a-493a-989c-7e1d2ecd69bc

History

Data availability:

Comments

Comment on this article

scite_

Cited by 66

See all cited by

- Version 1
- Version 1